VIP

01 · What is it?

The identity comes first.

VIP is a naturally occurring peptide involved in communication between nerves and several tissues. It affects smooth muscle, secretion and immune signaling. Its wide distribution makes blanket benefit claims particularly misleading.

Scientific classification: Vasoactive intestinal peptide; 28-amino-acid peptide hormone/neuropeptide

For example. It is a message used in several departments, so changing it can have more than one consequence.

02 · How does it work?

The signal, explained.

It activates receptors used by intestinal, vascular, neural and immune tissues. Internal messenger changes can influence muscle relaxation, secretion and immune communication.

The key research focus is VPAC1 and VPAC2 receptors. A target describes where an interaction may occur; it does not by itself establish a benefit.

03 · What happens after the signal?

Follow the downstream effects.

cAMP signaling can alter smooth-muscle tone, epithelial secretion and cytokine responses. These changes are context-dependent and do not establish broad respiratory or immune benefits.

To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.

04 · What is it commonly researched for?

The questions researchers are asking.

Scientists investigate intestinal physiology, vascular tone, inflammation and disease-specific aviptadil research.

These are areas of investigation, not promises about a Maison product.

05 · Body systems involved

Where the biology connects.

Digestive tract

Relevant to secretion, motility, epithelial transport or gut–brain signaling.

Cardiovascular system

Relevant to vascular, cardiac or metabolic outcomes only within the research described.

Immune system

Immune-cell signaling and cytokine responses are context-dependent.

Brain

Relevant to neural signaling, appetite, behavior or stress circuitry described above.

06 · Receptor / target profile

The molecular reference card.

Primary receptor or target

VPAC1 and VPAC2 receptors

Secondary interactions

No additional primary target established for the research claim discussed.

Where it is found

Intestinal, vascular, neural and immune tissues.

Activation, inhibition or interaction

These G-protein-coupled receptors activate adenylyl cyclase and cAMP-dependent signaling. Different receptor distributions produce different tissue effects.

Important downstream pathways

cAMP signaling can alter smooth-muscle tone, epithelial secretion and cytokine responses. These changes are context-dependent and do not establish broad respiratory or immune benefits.

07 · Evidence quality

What carries weight—and what does not.

A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.

08 · Who is studying it?

Follow the original research.

No current sponsor-led clinical development program was verified for this exact research identity. This does not prove that no study exists; consult current records and distinguish related molecules.

Regulatory context: No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.

Registry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.

09 · Research terminology

A small glossary for this page.

Explore the complete foundations glossary

10 · Research status & limitations

Keep the boundaries visible.

No approved medical use for this research identity was established in the sources reviewed. This is not a determination of authorization in every country. The research material discussed here must not be assumed equivalent to a licensed medicine.

Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.

The main evidence category here is human clinical research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.